Your browser doesn't support javascript.
loading
Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer.
Tonellotto, Fabiana; Bergmann, Anke; de Souza Abrahão, Karen; de Aguiar, Suzana Sales; Bello, Marcelo Adeodato; Thuler, Luiz Claudio Santos.
Afiliação
  • Tonellotto F; Department of Surgical Oncology, Mastology Service, Hospital do Câncer III, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil.
  • Bergmann A; Department of Clinical Research, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil.
  • de Souza Abrahão K; Department of Clinical Research, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil.
  • de Aguiar SS; Department of Clinical Research, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil.
  • Bello MA; Department of Surgical Oncology, Mastology Service, Hospital do Câncer III, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil.
  • Thuler LCS; Department of Clinical Research, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brasil.
Eur J Breast Health ; 15(2): 76-84, 2019 Apr.
Article em En | MEDLINE | ID: mdl-31001608
OBJECTIVE: This study aimed to evaluate the association of axillary lymph node ratio (LNR) and number of positive lymph nodes (pN) with the risk of breast cancer recurrence and death. MATERIALS AND METHODS: A retrospective cohort study of node-positive stage II and III breast cancer patients diagnosed and treated between 2008 and 2009 at the Brazilian National Cancer Institute (INCA), Brazil. Overall and disease-free survival curves for number of positive lymph nodes (pN) and lymph node ratio (LNR) risk groups were constructed using the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was performed using stepwise forward Cox regression models. RESULTS: In total, 628 women with node-positive breast cancer were included. Most patients (69.5%) had advanced clinical stage tumors (≥IIB). The median follow-up was 58 months (range: 3-92 months). The adjusted recurrence hazard of pN2 and pN3 patients was 2.47 (95% Confidence Interval [CI] 1.72-3.56) and 2.42 (1.62-3.60), respectively, compared to pN1 patients (p<0.001), while the hazard of intermediate (0.21-0.65) and high-risk (>0.65) LNR was 2.11 (1.49-3.00) and 3.19 (2.12-4.80), respectively, compared to low-risk LNR (≤0.20) patients (p<0.001). On the other hand, the hazard of death of pN2 and pN3 patients was 2.17 (1.42-3.30) and 2.41 (1.53-3.78), respectively (p<0.001), and the hazard of intermediate (0.21-0.65) and high-risk (>0.65) LNR patients was 1.70 (1.13-2.56) and 2.74 (1.75-4.28), respectively (p≤0.001). CONCLUSION: Higher pN and LNR were associated with shorter disease-free survival and overall survival times.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Eur J Breast Health Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Turquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Eur J Breast Health Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Turquia